Format

Send to

Choose Destination
Expert Rev Cardiovasc Ther. 2016 Dec;14(12):1315-1323. Epub 2016 Sep 20.

Renal dysfunction and transcatheter aortic valve implantation outcomes.

Author information

1
a Division of Cardiology, Ferrarotto Hospital , University of Catania , Catania , Italy.
2
b Division of Cardiology - Department of Advanced Biomedical Sciences , Federico II University , Naples , Italy.
3
c Excellence Through Newest Advances (ETNA) Foundation , Catania , Italy.

Abstract

Transcatheter aortic valve implantation (TAVI) underwent progressive improvements until it became the default therapy for inoperable patients, and a recommended therapy in high-risk operable patients with symptomatic severe aortic stenosis. Recent evidence will further support TAVI as treatment for a growing number of patients. Areas covered: This review will discuss on the current knowledge about the role of both pre-procedural chronic kidney disease (CKD) and post-procedural acute kidney injury (AKI) in adult patients with severe aortic stenosis undergoing TAVI. Expert commentary: Pre-procedural CKD is one of the most frequent comorbidities of TAVI patients and has been found to significantly worsen patients' prognosis at short and long-term follow-up. Similarly, post-procedural AKI is a frequent and relevant complication associated with increased mortality. The risk stratification of the patient, the prevention of complications and the appropriate post-procedural management are the main focus of the future research aimed at further improving clinical outcomes of TAVI patients.

KEYWORDS:

TAVI; acute kidney injury; chronic kidney disease; mortality; renal dysfunction

PMID:
27636535
DOI:
10.1080/14779072.2016.1234377
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center